Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels

University of California San Diego

Status and phase: Completed; Phase 4

Conditions: Dyslipidemias

Treatments: Drug: Placebo; Drug: 40 mg Pravastatin (Pravachol); Drug: 20 mg Simvastatin

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00330980

394

R01HL063055 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Statins are cholesterol-lowering medications that are often prescribed for individuals with high cholesterol and who are at risk for heart disease. Preliminary research has shown that statins may have other effects on the body that are unrelated to the heart. The purpose of this study is to evaluate the impact of statins on mood, mental processes, aggression, and serotonin levels.

Full description

Individuals at risk for coronary artery disease are often prescribed statins, which are medications that reduce the amount of cholesterol in the blood. By lowering cholesterol levels, these individuals have a lower incidence of heart disease, heart attacks, and stroke. Simvastatin and pravastatin are two common statins that are often prescribed for individuals with high cholesterol. While statins are effective at lowering cholesterol levels, their effect on mood, behavior, and aggression has not been widely studied. Preliminary research has shown that lowering cholesterol levels may lead to an increase in aggressive behaviors and a change in cognitive function. Serotonin, a type of neurotransmitter, is believed to play an important role in the regulation of mood, as well as behavior and cognition. The direct effect of statins on serotonin levels remains unknown. The purpose of this study is to evaluate the effect of simvastatin and pravastatin on mood, cognition, aggression, and serotonin levels.

This study will enroll individuals who do not currently take cholesterol-lowering medications. Participants will be randomly assigned to receive 20 mg of simvastatin, 40 mg of pravastatin, or placebo for 6 months. Study visits will occur at baseline and Months 1, 3, 6, and 8. Height, weight, and waist circumference will be measured at all study visits. Blood and urine will be collected for laboratory testing, and standardized psychological questionnaires will assess cognition, aggression, mental flexibility, memory, depression, sleep quality, and quality of life at Months 1, 6, and 8. At Month 3, medication side effects will be monitored and a liver function test will be performed. Participants' partners will take part in a telephone interview at this time. At baseline and Month 6, some participants will undergo cardiac reactivity testing. During this procedure, participants will be videotaped and monitored for vital sign changes (blood pressure and heart rate) while they talk about potentially stressful situations.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• LDL cholesterol level between 115-190 mg/dL
• Able to fast prior to blood draw
• Able to comfortably read and write in English
• Able and willing to refrain from donating whole blood during study participation
• Willing to abstain from consuming large amounts of grapefruit juice

Exclusion criteria

• Current use of lipid-lowering medications
• Symptomatic atherosclerotic disease, such as coronary artery disease, kidney failure or insufficiency, peripheral arterial disease, or cerebrovascular disease
• Cancer
• HIV infected
• Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis)
• Active liver disease or unexplained persistent elevated transaminase levels
• Major surgery or hospitalization in the 3 months prior to study entry
• Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any "azole" antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors
• Female of childbearing potential
• Current participation in another clinical trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,000 participants in 3 patient groups, including a placebo group

1

Experimental group

Description:

Participants will receive 20 mg of simvastatin for 6 months.

Treatment:

Drug: 20 mg Simvastatin

2

Experimental group

Description:

Participants will receive 40 mg of pravastatin for 6 months.

Treatment:

Drug: 40 mg Pravastatin (Pravachol)

3

Placebo Comparator group

Description:

Participants will receive placebo for 6 months.

Treatment:

Drug: Placebo